Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)
Status:
Terminated
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The study is a single centre, single arm, open-label, proof of concept study enrolling 20
adult primary liver transplant recipients with genotype 1 HCV infection. Subjects will
receive Sofosbuvir (SOF) and Ledipasvir (LDV) starting at time of liver transplantation (OLT)
and continues for 12 weeks. Subjects will be receive 24 week post-treatment follow up.